# US 2003/0077708 A1 · Antigen presenting system and methods for activation of T-cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0077708 A1
- Document ID: US20030077708A1
- Status: Published application
- Kind: A1
- Application number: 10/105,678
- Filed: 2002-03-25
- Published: 2003-04-24
- Earliest claimed: 1995-03-08
- Assignees: The Scripps Research Institute
- Inventors: Zeling Cai; Jonathan Sprent; Anders Brunmark; Michael Jackson; Per A. Peterson
- Web page: https://patentgrep.com/patent/US20030077708A1

## CPC

- C12N 5/0601: {Invertebrate cells or tissues, e.g. insect cells; Culture media therefor}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/428: {Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor}
- A61K 40/46: Viral antigens
- A61P 31/12: Antivirals
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/005: from viruses
- C07K 14/70503: {Immunoglobulin superfamily}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C12N 5/0636: {T lymphocytes}
- C12N 15/85: for animal cells
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2501/50: Cell markers; Cell surface determinants
- C12N 2501/51: B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
- C12N 2502/50: invertebrate cells
- C12N 2502/99: genetically modified cells
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/18822: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/20222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2830/002: inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C12N 2830/75: from invertebrates
- C12N 2830/80: from vertebrates
- Y10S 530/812: Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S 530/827: Proteins from mammals or birds
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

Materials and methods for activating T lymphocytes with specificity for particular antigenic peptides are described, as well as the use of activated T lymphocytes in vitro for the treatment of a variety of disease conditions. In particular, a method for producing a synthetic antigen presenting cell line for activating T lymphocytes to a specific peptide is described.

## Claims

### Claim 1

A synthetic antigen presenting cell line for activating T-cell lymphocytes to a specific peptide and comprising:
a) a Class I MHC heavy chain gene operably linked to a first promoter, said gene expressing a Class I MHC heavy chain;
b) a β-2 microglobulin gene operably linked to a second promoter, said gene expressing a β-2 microglobulin that forms a MHC molecule with the MHC heavy chain; and
c) a gene for an assisting molecule operably linked to a third promoter, said gene expressing an assisting molecule which is a member of the group consisting of B7.1, B7.2, ICAM-1, ICAM-2, ICAM-3 and LFA-3, and that interacts with a molecule on the T-cell lymphocytes;
with the proviso that at least one of said MHC gene, said β-2 microglobulin gene and said assisting molecule gene is not present in the cells from which the cell line is derived, such that the MHC molecule binds to a peptide, and the MHC molecule and the assisting molecule are presented on the surface of an insect cell of said cell line in sufficient numbers to activate a population of T-cell lymphocytes against the peptide when the peptide is bound to the MHC molecule.

### Claim 2 (depends on 1)

The cell line of claim 1 wherein the assisting molecule is a costimulatory molecule.

### Claim 3 (depends on 1)

The cell line of claim 1 wherein the cell line is derived from a first species and the MHC heavy chain gene is from a second species.

### Claim 4 (depends on 3)

The cell line of claim 3 wherein the first species is a poikilotherm and the second species is a homeotherm.

### Claim 5 (depends on 1)

The cell line of claim 1 wherein the assisting molecule is an adhesion molecule.

### Claim 6 (depends on 5)

The cell line of claim 5 wherein the adhesion molecule is a member of the group consisting of ICAM-1, ICAM-2, ICAM-3 and LFA-3.

### Claim 7 (depends on 1)

The cell line of claim 1 having a gene for a first assisting molecule and a gene for a second assisting molecule.

### Claim 8 (depends on 7)

The cell line of claim 7 wherein the first assisting molecule is a costimulatory molecule and the second assisting molecule is an adhesion molecule.

### Claim 9 (depends on 1)

The cell line of claim 1 wherein at least one promoter is inducible.

### Claim 10 (depends on 9)

The cell line of claim 9 wherein the first promoter is inducible.

### Claim 11 (depends on 1)

The cell line of claim 1 wherein the peptide is bound to the MHC molecule within the cell.

### Claim 12 (depends on 1)

The cell line of claim 1 wherein the MHC molecule is presented empty on the surface of the cell.

### Claim 13

A stable poikilotherm cell line used to stimulate human T-cell lymphocytes comprising:
a) a Class I MHC gene operably linked to a first inducible promoter, said gene expressing a Class I MHC heavy chain;
b) a β-2 microglobulin gene operably linked to a second promoter, said gene expressing a β-2 microglobulin that forms a MHC molecule with the MHC heavy chain; and
c) a gene for an assisting molecule operably linked to a third promoter, said gene expressing an assisting molecule which is a member of the group consisting of B7.1, B7.2, ICAM-1, ICAM-2, ICAM-3 and LFA-3, and that interacts with a molecule on the T-cell lymphocytes;
such that a cell of the cell line assembles empty MHC molecules that bind to a peptide, and the MHC molecule and the assisting molecule are presented on the surface of a cell of the cell line in sufficient numbers to activate a population of T-cell lymphocytes against the peptide when the peptide is bound to the MHC molecule.

### Claim 14 (depends on 13)

The cell line of claim 13 wherein the assisting molecule is a costimulatory molecule.

### Claim 15 (depends on 13)

The cell line of claim 13 wherein the assisting molecule is an adhesion molecule.

### Claim 16 (depends on 15)

The cell line of claim 15 wherein the adhesion molecule is ICAM-1.

### Claim 17 (depends on 13)

The cell line of claim 13 having a gene for a first assisting molecule and a gene for a second assisting molecule.

### Claim 18 (depends on 17)

The cell line of claim 17 wherein the first assisting molecule is a costimulatory molecule and the second assisting molecule is an adhesion molecule.

### Claim 19

A stable poikilotherm cell line used to stimulate human T-cell lymphocytes comprising:
a) a Class I MHC gene operably linked to a first promoter, said gene expressing a Class I MHC heavy chain;
b) a β-2 microglobulin gene operably linked to a second promoter, said gene expressing a β-2 microglobulin that forms a MHC molecule with the MHC heavy chain; and
c) a gene for a costimulatory molecule operably linked to a third promoter and said gene expressing a costimulatory molecule which is a B7.1 molecule or a B7.2 molecule that interacts with a molecule on the T-cell lymphocytes;
d) a gene for an adhesion molecule operably linked to a fourth promoter and said gene expressing an adhesion molecule that interacts with a cooperative adhesion molecule on the T-cell lymphocytes and is a member of the group consisting of ICAM-1, ICAM-2, ICAM-3 and LFA-3.
such that the cell is capable of assembling the MHC heavy chain and the β-2 microglobulin into a MHC molecule that binds to a peptide, and transporting MHC molecule, costimulatory molecule and adhesion molecule to the surface of the cell in sufficient numbers to activate a population of T-cell lymphocytes against the peptide when the peptide is bound to the MHC molecule.

### Claim 20 (depends on 19)

The cell line of claim 19 wherein at least one of the promoters is inducible.

### Claim 21 (depends on 19)

The cell line of claim 19 wherein the peptide is bound to the MHC molecule within the cell.

### Claim 22 (depends on 19)

The cell line of claim 19 wherein the MHC molecule is presented empty on the surface of the cell.
